JP2018513193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513193A5 JP2018513193A5 JP2017555572A JP2017555572A JP2018513193A5 JP 2018513193 A5 JP2018513193 A5 JP 2018513193A5 JP 2017555572 A JP2017555572 A JP 2017555572A JP 2017555572 A JP2017555572 A JP 2017555572A JP 2018513193 A5 JP2018513193 A5 JP 2018513193A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- group
- compound
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 21
- 230000003115 biocidal effect Effects 0.000 claims 16
- 244000005700 microbiome Species 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000004185 ester group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000001678 irradiating effect Effects 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 1
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 108010028921 Lipopeptides Proteins 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- 229910005965 SO 2 Inorganic materials 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical group [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000879 imine group Chemical group 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims 1
- 229960001907 nitrofurazone Drugs 0.000 claims 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims 1
- 229960001180 norfloxacin Drugs 0.000 claims 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims 1
- 229960001019 oxacillin Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 229960005266 polymyxin b Drugs 0.000 claims 1
- 230000008261 resistance mechanism Effects 0.000 claims 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims 1
- 229960000885 rifabutin Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 125000001174 sulfone group Chemical group 0.000 claims 1
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- 125000003375 sulfoxide group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 150000007970 thio esters Chemical group 0.000 claims 1
- 125000004149 thio group Chemical group *S* 0.000 claims 1
- 125000000101 thioether group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- 150000003952 β-lactams Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149738P | 2015-04-20 | 2015-04-20 | |
| US62/149,738 | 2015-04-20 | ||
| US201662306165P | 2016-03-10 | 2016-03-10 | |
| US62/306,165 | 2016-03-10 | ||
| PCT/US2016/028418 WO2016172193A1 (en) | 2015-04-20 | 2016-04-20 | Antibiotic sensitivity-restoring and photosensitive agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513193A JP2018513193A (ja) | 2018-05-24 |
| JP2018513193A5 true JP2018513193A5 (enExample) | 2019-05-30 |
Family
ID=57128517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555572A Pending JP2018513193A (ja) | 2015-04-20 | 2016-04-20 | 抗生物質感受性回復及び感光性薬剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9834514B2 (enExample) |
| EP (1) | EP3285796A4 (enExample) |
| JP (1) | JP2018513193A (enExample) |
| CN (1) | CN107735101B (enExample) |
| WO (1) | WO2016172193A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3285796A4 (en) * | 2015-04-20 | 2018-12-12 | New Mexico Tech Research Foundation | Antibiotic sensitivity-restoring and photosensitive agents |
| KR20220061106A (ko) | 2019-08-02 | 2022-05-12 | 코이트 헬스 오와이 | 전신적으로 적용하는 항생제의 항균 작용을 강화하는 방법 |
| CN115181050B (zh) * | 2022-08-03 | 2024-01-30 | 石河子大学 | 一种2-苯基吲哚衍生物的制备方法及其用途 |
| CN120131638A (zh) * | 2025-03-06 | 2025-06-13 | 扬州大学 | 具有吸电子基团的吲哚类化合物在抑制质粒接合转移中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3978224A (en) | 1975-07-01 | 1976-08-31 | Schering Corporation | Antimicrobial halo-substituted-2-cyanoethylaminoalkyl-3-phenyl-indoles |
| WO1994010198A1 (en) | 1992-11-02 | 1994-05-11 | Yves Claude Nicolau | Method of reducing multidrug resistance in cells and tissues |
| WO2004062674A2 (en) * | 2003-01-07 | 2004-07-29 | Paratek Pharmaceuticals, Inc. | Substituted polyamines as inhibitors of bacterial efflux pumps |
| US7825136B2 (en) * | 2003-07-10 | 2010-11-02 | Vertex Pharmaceuticals Incorporated | Potentiators of antibacterial activity |
| US20120135092A1 (en) | 2005-03-07 | 2012-05-31 | Scott Fain Singleton | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS |
| US20060199768A1 (en) | 2005-03-07 | 2006-09-07 | University Of North Carolina At Chapel Hill | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens |
| WO2008019292A2 (en) | 2006-08-04 | 2008-02-14 | Trustees Of Boston University | Compositions and methods for potentiating antibiotic activity |
| CA2686997A1 (en) * | 2007-05-11 | 2008-11-20 | Mpex Pharmaceuticals, Inc. | Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof |
| WO2010054102A2 (en) * | 2008-11-05 | 2010-05-14 | Mpex Pharmaceuticals, Inc. | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof |
| JP5852007B2 (ja) * | 2009-12-18 | 2016-02-03 | コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ | 抗微生物剤の増進剤としてのカルコン類 |
| WO2012112548A2 (en) * | 2011-02-15 | 2012-08-23 | The Regents Of The University Of California | Firmocidin, an antimicrobial molecule produced by staphylococcus epidermidis |
| US9282738B2 (en) * | 2011-07-11 | 2016-03-15 | Wisconsin Alumni Research Foundation | Antimicrobial compositions and methods of use thereof |
| KR101385196B1 (ko) * | 2012-05-17 | 2014-04-14 | 주식회사 유니크메디케어 | 광 조사를 이용한 광감각제―펩타이드를 유효성분으로 포함하는 발모 개선 또는 촉진용 조성물 및 이를 이용한 방법 |
| EP3154534B1 (en) * | 2014-06-13 | 2020-02-12 | University Of Rochester | Small molecule efflux pump inhibitors |
| EP3285796A4 (en) * | 2015-04-20 | 2018-12-12 | New Mexico Tech Research Foundation | Antibiotic sensitivity-restoring and photosensitive agents |
-
2016
- 2016-04-20 EP EP16783753.3A patent/EP3285796A4/en not_active Withdrawn
- 2016-04-20 JP JP2017555572A patent/JP2018513193A/ja active Pending
- 2016-04-20 US US15/133,430 patent/US9834514B2/en active Active
- 2016-04-20 WO PCT/US2016/028418 patent/WO2016172193A1/en not_active Ceased
- 2016-04-20 CN CN201680036144.XA patent/CN107735101B/zh active Active
-
2017
- 2017-10-31 US US15/798,545 patent/US10239834B2/en active Active
-
2019
- 2019-02-04 US US16/266,684 patent/US20190337893A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050085446A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| JP2018513193A5 (enExample) | ||
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| CN101175531B (zh) | 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物 | |
| JP2006523216A5 (enExample) | ||
| EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
| JP2018513188A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2015521617A5 (enExample) | ||
| US12414958B2 (en) | Medicament and use thereof for treating bacterial infections involving biofilm | |
| JP2013500977A5 (enExample) | ||
| US20250144060A1 (en) | Compositions and methods for treating biofilms | |
| JP2017508817A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| JP2014510782A5 (enExample) | ||
| US20070049552A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| AU2020337892B2 (en) | Methods of treatment using BCN057 and BCN512 | |
| EA202191144A1 (ru) | Состав ингибитора bcl-2 на основе циклодекстрина | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| CN103608013A (zh) | 包含抗菌剂和他唑巴坦的组合物 | |
| US8623864B2 (en) | Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance | |
| JP2011502103A (ja) | カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物 | |
| JP2006513188A (ja) | ベンゾキノリンジカルボン酸抗菌薬の組成物 | |
| Rosenblatt et al. | Gram-negative bacterial endocarditis in narcotic addicts |